Display options
Cite
Acuff SF, Tucker JA, Murphy JG. Behavioral economics of substance use: Understanding and reducing harmful use during the COVID-19 pandemic. Exp Clin Psychopharmacol. 2020;29(6):739-749doi: 10.1037/pha0000431.
Acuff, S. F., Tucker, J. A., & Murphy, J. G. (2021). Behavioral economics of substance use: Understanding and reducing harmful use during the COVID-19 pandemic. Experimental and clinical psychopharmacology, 29(6), 739-749. https://doi.org/10.1037/pha0000431
Acuff, Samuel F, et al. "Behavioral economics of substance use: Understanding and reducing harmful use during the COVID-19 pandemic." Experimental and clinical psychopharmacology vol. 29,6 (2021): 739-749. doi: https://doi.org/10.1037/pha0000431
Acuff SF, Tucker JA, Murphy JG. Behavioral economics of substance use: Understanding and reducing harmful use during the COVID-19 pandemic. Exp Clin Psychopharmacol. 2021 Dec;29(6):739-749. doi: 10.1037/pha0000431. Epub 2020 Nov 09. PMID: 33166163; PMCID: PMC8163023.
Copy Download .nbib Format: NLM
Share it on

Exp Clin Psychopharmacol. 2021 Dec;29(6):739-749. doi: 10.1037/pha0000431. Epub 2020 Nov 09.

Behavioral economics of substance use: Understanding and reducing harmful use during the COVID-19 pandemic.

Experimental and clinical psychopharmacology

Samuel F Acuff, Jalie A Tucker, James G Murphy

Affiliations

  1. Department of Psychology.
  2. Department of Health and Human Behavior.

PMID: 33166163 PMCID: PMC8163023 DOI: 10.1037/pha0000431

Abstract

Behavioral economic research demonstrates that alcohol and drug consumption is (a) an inverse function of constraints on access to the substance and (b) a direct function of constraints on access to alternative rewards. Physical distancing interventions and economic consequences of the COVID-19 pandemic have resulted in unprecedented reductions in many of the constraints on substance use and in critical evolutionarily salient sources of alternative reward, such as social interaction, physical activity, leisure activities and hobbies, and academic and occupational pursuits. Thus, behavioral economics suggests that the pandemic and necessary public health response have created a "perfect storm" for exacerbation of individual-level and population-level substance use problems and also points to multilevel intervention strategies. We summarize this perspective and research by highlighting 3 critical behavioral processes that will influence drug and alcohol consumption. First, the sudden absence of many effective constraints on substance use (work, school, community, or service obligations) will reduce the actual and perceived cost of use. Second, physical distancing measures will reduce the availability, and increase the cost, of many rewarding substance-free activities and commodities. Third, increased uncertainty around current and future events increases discounting of delayed rewards. These effects will be especially pernicious among populations with existing health disparities. Next, we outline interventions suggested by behavioral economics to mitigate the impact of COVID-19 on substance use that are aimed at increasing perceived costs of use; increasing access to substance-free activities, including treatment; and lengthening the timeframe for behavioral allocation and altering environmental contexts to promote healthy choices. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

References

  1. J Consult Clin Psychol. 2019 Jul;87(7):657-669 - PubMed
  2. J Stud Alcohol Drugs. 2017 Jan;78(1):106-112 - PubMed
  3. Psychol Addict Behav. 2017 Dec;31(8):897-906 - PubMed
  4. Exp Clin Psychopharmacol. 2006 May;14(2):219-27 - PubMed
  5. J Abnorm Psychol. 1988 May;97(2):181-95 - PubMed
  6. Psychol Addict Behav. 2020 Feb;34(1):136-146 - PubMed
  7. PLoS One. 2012;7(7):e40316 - PubMed
  8. Psychopharmacology (Berl). 2011 Aug;216(3):305-21 - PubMed
  9. Exp Clin Psychopharmacol. 2006 Aug;14(3):339-49 - PubMed
  10. Health Promot Pract. 2020 Jan;21(1):70-79 - PubMed
  11. Alcohol Res. 2016;38(1):83-94 - PubMed
  12. Addiction. 2012 Feb;107(2):289-99 - PubMed
  13. Psychol Addict Behav. 2018 Nov;32(7):792-799 - PubMed
  14. Psychol Addict Behav. 2013 Dec;27(4):909-20 - PubMed
  15. JAMA. 2007 Nov 28;298(20):2415-7 - PubMed
  16. Drug Alcohol Depend. 2018 Jan 1;182:33-39 - PubMed
  17. Addiction. 2011 Jan;106(1):178-87 - PubMed
  18. J Consult Clin Psychol. 2012 Oct;80(5):876-86 - PubMed
  19. Clin Psychol Sci. 2017 Jul;5(4):683-697 - PubMed
  20. Behav Brain Funct. 2007 Jan 10;3:1 - PubMed
  21. Behav Res Ther. 1973 Feb;11(1):91-104 - PubMed
  22. Nicotine Tob Res. 2015 Mar;17(3):292-8 - PubMed
  23. J Abnorm Psychol. 1983 Nov;92(4):408-16 - PubMed
  24. J Subst Abuse Treat. 2014 Jul;47(1):1-9 - PubMed
  25. Lancet Infect Dis. 2020 May;20(5):533-534 - PubMed
  26. Addict Behav. 2005 Jan;30(1):19-27 - PubMed
  27. Health Psychol. 2005 Jul;24(4S):S49-56 - PubMed
  28. Behav Pharmacol. 2000 Feb;11(1):87-91 - PubMed
  29. Addiction. 1998 Mar;93(3):321-35 - PubMed
  30. Addict Behav. 2009 Dec;34(12):993-9 - PubMed
  31. Addiction. 2018 Mar;113(3):535-544 - PubMed
  32. J Stud Alcohol Drugs. 2012 Jul;73(4):686-98 - PubMed
  33. Addict Behav. 2017 Mar;66:1-6 - PubMed
  34. Clin Psychol Rev. 2019 Jun;70:79-90 - PubMed
  35. Psychol Addict Behav. 2017 Jun;31(4):488-496 - PubMed
  36. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7582-7 - PubMed
  37. Addiction. 2019 Jan;114(1):112-118 - PubMed
  38. Psychol Addict Behav. 2015 Mar;29(1):34-48 - PubMed
  39. Addiction. 2019 Jan;114(1):69-80 - PubMed
  40. NIDA Res Monogr. 1994;145:113-30 - PubMed
  41. J Exp Anal Behav. 1980 Sep;34(2):219-38 - PubMed
  42. BMC Public Health. 2019 Jun 13;19(1):742 - PubMed
  43. Addiction. 2020 May;115(5):817-831 - PubMed

Publication Types

Grant support